143 related articles for article (PubMed ID: 11321040)
1. Apoptosis in multiple myeloma: therapeutic implications.
Chauhan D; Anderson KC
Apoptosis; 2001; 6(1-2):47-55. PubMed ID: 11321040
[TBL] [Abstract][Full Text] [Related]
2. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
Kizaki M; Tabayashi T
J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy for multiple myeloma.
Anderson KC
Semin Hematol; 2001 Jul; 38(3):286-94. PubMed ID: 11486317
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic signaling in multiple myeloma: therapeutic implications.
Chauhan D; Hideshima T; Anderson KC
Int J Hematol; 2003 Aug; 78(2):114-20. PubMed ID: 12953804
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma: Implementing signaling pathways and molecular biology in clinical trials.
Bazzi M; Badros A
Cancer Biol Ther; 2010 Nov; 10(9):830-8. PubMed ID: 21045554
[TBL] [Abstract][Full Text] [Related]
6. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
7. Signal transduction and myeloma: new targets, new hope.
Lonial S; Waller EK; Simons JW; Heffner LT
Cancer Biol Ther; 2003; 2(4):310-9. PubMed ID: 14508098
[TBL] [Abstract][Full Text] [Related]
8. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.
Ramakrishnan V; Kumar S
Leuk Lymphoma; 2018 Nov; 59(11):2524-2534. PubMed ID: 29322846
[TBL] [Abstract][Full Text] [Related]
9. Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells.
Renoir JM; Bouclier C; Seguin A; Marsaud V; Sola B
J Mol Endocrinol; 2008 Mar; 40(3):101-12. PubMed ID: 18316469
[TBL] [Abstract][Full Text] [Related]
10. Targeting signaling pathways in multiple myeloma.
Federica C; Antonio P; Guido T; Mario B
Curr Pharm Biotechnol; 2006 Dec; 7(6):407-13. PubMed ID: 17168656
[TBL] [Abstract][Full Text] [Related]
11. Novel biologically based therapeutic strategies in myeloma.
Gupta D; Hideshima T; Anderson KC
Rev Clin Exp Hematol; 2002 Sep; 6(3):301-24. PubMed ID: 12616700
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
Hideshima T; Anderson KC
Nat Rev Cancer; 2002 Dec; 2(12):927-37. PubMed ID: 12459731
[TBL] [Abstract][Full Text] [Related]
13. Signaling Pathways and Emerging Therapies in Multiple Myeloma.
Ramakrishnan V; D'Souza A
Curr Hematol Malig Rep; 2016 Apr; 11(2):156-64. PubMed ID: 26922744
[TBL] [Abstract][Full Text] [Related]
14. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments.
Hu J; Hu WX
Cancer Lett; 2018 Feb; 414():214-221. PubMed ID: 29174802
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications.
Chauhan D; Anderson KC
Apoptosis; 2003 Aug; 8(4):337-43. PubMed ID: 12815276
[TBL] [Abstract][Full Text] [Related]
16. Oleocanthal inhibits proliferation and MIP-1α expression in human multiple myeloma cells.
Scotece M; Gómez R; Conde J; Lopez V; Gómez-Reino JJ; Lago F; Smith AB; Gualillo O
Curr Med Chem; 2013; 20(19):2467-75. PubMed ID: 23521677
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
[TBL] [Abstract][Full Text] [Related]
18. Towards a new age in the treatment of multiple myeloma.
Piazza FA; Gurrieri C; Trentin L; Semenzato G
Ann Hematol; 2007 Mar; 86(3):159-72. PubMed ID: 17205287
[TBL] [Abstract][Full Text] [Related]
19. Targeting Bcl-2 for the treatment of multiple myeloma.
Touzeau C; Maciag P; Amiot M; Moreau P
Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
[TBL] [Abstract][Full Text] [Related]
20. Estrogenic or antiestrogenic therapies for multiple myeloma?
Sola B; Renoir JM
Mol Cancer; 2007 Sep; 6():59. PubMed ID: 17888187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
